Januvia 100mg. Sitagliptin 100mg. Buy Januvia online 

What is Januvia?

Januvia 100mg (Sitagliptin) is an oral hypoglycemic drug which belongs to the group of medicines called selective inhibitors of dipeptidyl peptidase-4.

Januvia increasesthe concentration of glucagon-like peptide-1 and glucose-dependent insulinotropic peptide in blood plasma. Thus, increases insulin secretion, reduces glucagon secretion and glycosylated hemoglobin levels in patients with diabetes mellitus type II. The level of glycemia is decreased as well.

Is used to treat non-insulin dependent diabetes mellitus (II type).

Pharmacological properties

Januvia 100mg (Sitagliptin) is an oral hypoglycemic drug, a selective inhibitor of dipeptidyl peptidase-4. It works by increasing the concentration of glucagon-like peptide-1 and glucose-dependent insulinotropic peptide in blood plasma. It helps increase insulin secretion, causes reduction of glucagon secretion, glycosylated hemoglobin levels and blood glucose levels in patients with diabetes mellitus type II. Januvia is a highly selective inhibitor of dipeptidyl peptidase-4 (DPP-4).

Sitagliptin is different in structure and action mechanism from insulin, sulfonylureas and biguanide derivatives, analogues of glucagon-like peptide-1 agonists, PPAR-gamma (gamma receptor, peroxisome proliferator-activated) inhibitors of alpha-glycosidase, amylin analogues.

Inhibition of dipeptidyl peptidase-4 leads to increased concentrations of two known incretins: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). These incretins are secreted into the intestine and their concentration is increased in response to food intake. They are part of the internal physiological regulation of glucose homeostasis. At normal or elevated blood glucose levels these incretins contribute to increase of insulin synthesis and secretion of its beta-cells of the pancreas by cAMP-associated signaling intracellular mechanisms.

Glucagon-like peptide-1 also contributes to the suppression of increased glucagon secretion by alpha-cells in the pancreas. Reducing the concentration of glucagon, accompanied by increased levels of insulin helps reduce hepatic glucose production, resulting in a decrease of glycemia levels.